BMJ 2007;335:223 (4 August) by Janice Hopkins Tanne.
Rosiglitazone (Avandia) and pioglitazone (Actos) DOUBLED the risk of heart failure in patients with type 2 diabetes (Diabetes Care 2007;30:2148-53).
The authors said that although drugs in the thiazolidinedione class were known to increase the risk of heart failure in patients with type 2 diabetes, the magnitude of the risk had not been evaluated.
One in every 50 patients with type 2 diabetes taking one of these drugs would develop heart failure in a period of 26 months and need admission to hospital.
Heart failure occurred at low and high doses of the drugs and among people younger than 60 years as well as among older people.
The author, said this is nothing NEW, but it is still something very worthwhile to know for GP’s.
If you want to read the extract just CLICK HERE.
[...] an interesting post today on TYPE 2 DIABETES AND HEART FAILUREHere’s a quick [...]
Thx for your comments.
I found it interesting as well. And very worthwhile for doctors to be reminded off.
[...] asehley wrote a fantastic post today on “TYPE 2 DIABETES AND HEART FAILURE”Here’s ONLY a quick extractThe authors said that although drugs in the thiazolidinedione class were known to increase the risk of heart failure in patients with type 2 diabetes, the magnitude of the risk had not been evaluated. One in every 50 patients with type … [...]